T. Peter Kingham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
T. Peter Kingham has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Eileen Mary O'Reilly
Weill Cornell Medicine
2 shared publications - Kevin C. Soares
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
2 shared publications - William Robert Jarnagin
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications Abigael Akinwale
African Research Group for Oncology Ile‐Ife Nigeria
1 shared publicationAdebola Adedimeji
Department of Epidemiology and Prevention Wake Forest University Winston‐Salem North Carolina USA
1 shared publicationAdeleye D. Omisore
African Research Group for Oncology Ile‐Ife Nigeria
1 shared publication
Latest Publications
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (8) , e2501261
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
PURPOSE: Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected and nonresected ICC. METHODS: Adults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes. RESULTS: Of the 795 patients analyzed, 25% had IDH1/2 mutations ( IDH mut) and 43% underwent resection. Median overall survival (OS) of the cohort was 32 months in IDH mut and 28 months for IDH wt ( P = .2). High-risk genetic alterations ( TP53 mut, KRAS mut, and CDKN2A del) were more frequent in IDH wild-type ( IDH wt; odds ratio, 2.26; q < 0.001). OS was 19 months in patients with high-risk alterations versus 40 months in patients without ( P < .001). In resected patients, recurrence-free survival (RFS) in IDH mut was 20 months versus 14 months for IDH wt ( P = .018), and OS was 69 months versus 50 months, respectively ( P = .2). However, after controlling for high-risk alterations, the potential benefit of IDH mut was no longer apparent (RFS: hazard ratio [HR], 0.78; P = .095; OS: HR, 0.88; P = .4). In unresectable IDH mut patients, progression-free survival was 9.4 months versus 9.1 months for IDH wt ( P = .7), and OS was 22 months versus 18 months, respectively ( P = .13). There remained no differences after controlling for high-risk alterations. IDH status was not a significant survival predictor in multivariable models. CONCLUSION: In this cohort of patients with ICC, IDH mut was not an independent predictor of survival, after controlling for high-risk alterations and clinical variables. IDH mutational status alone should, therefore, not be used to guide prognosis.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (8) , e2501261
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
PURPOSE: Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected and nonresected ICC. METHODS: Adults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes. RESULTS: Of the 795 patients analyzed, 25% had IDH1/2 mutations ( IDH mut) and 43% underwent resection. Median overall survival (OS) of the cohort was 32 months in IDH mut and 28 months for IDH wt ( P = .2). High-risk genetic alterations ( TP53 mut, KRAS mut, and CDKN2A del) were more frequent in IDH wild-type ( IDH wt; odds ratio, 2.26; q < 0.001). OS was 19 months in patients with high-risk alterations versus 40 months in patients without ( P < .001). In resected patients, recurrence-free survival (RFS) in IDH mut was 20 months versus 14 months for IDH wt ( P = .018), and OS was 69 months versus 50 months, respectively ( P = .2). However, after controlling for high-risk alterations, the potential benefit of IDH mut was no longer apparent (RFS: hazard ratio [HR], 0.78; P = .095; OS: HR, 0.88; P = .4). In unresectable IDH mut patients, progression-free survival was 9.4 months versus 9.1 months for IDH wt ( P = .7), and OS was 22 months versus 18 months, respectively ( P = .13). There remained no differences after controlling for high-risk alterations. IDH status was not a significant survival predictor in multivariable models. CONCLUSION: In this cohort of patients with ICC, IDH mut was not an independent predictor of survival, after controlling for high-risk alterations and clinical variables. IDH mutational status alone should, therefore, not be used to guide prognosis.
Customized early detection of colorectal cancer in Nigeria identifies advanced adenomas and early‐stage disease
Background: Colorectal cancer (CRC) incidence is increasing in low‐ and middle‐income countries, where late‐stage presentation is common and survival rates remain poor. Early‐detection programs are critical to improving outcomes. Methods: A longitudinal early‐detection study was conducted in Osun State, Nigeria. A 6‐month community awareness campaign was implemented with posters, radio jingles, social media, and messaging disseminated via health and religious institutions. CRC knowledge was assessed before and after the intervention with the validated Bowel Cancer Awareness Measure questionnaire. Individuals with indicators of CRC were referred from peripheral facilities to an early‐diagnosis (ED) clinic at a tertiary center. Demographic data, presenting features, and diagnostic outcomes were prospectively recorded. The primary end point was detection of advanced adenomas and CRC. Results: Of 497 eligible participants, 322 (64.8%) completed pre‐ and postcampaign surveys. Awareness of CRC improved from 54 (16.8%) to 311 (96.9%) ( p < .001). Good knowledge of CRC risk factors and symptoms also increased significantly ( p < .001). A total of 329 individuals were navigated to the ED clinic; 168 (51.1%) were eligible for the protocol, and 116 (73.0%) completed colonoscopy. CRC was diagnosed in four patients (3.4%), with stage 0 ( n = 2), II ( n = 1), and III ( n = 1). Advanced adenomas were identified in 11% of patients (13 of 116) who underwent colonoscopy. Conclusions: Combining community engagement with patient navigation significantly increased CRC awareness and enabled the detection of advanced adenomas and early‐stage cancers. Expanding this model to a national level is recommended to evaluate broader impact, cost‐effectiveness, and potential implementation challenges.
Customized early detection of colorectal cancer in Nigeria identifies advanced adenomas and early‐stage disease
Background: Colorectal cancer (CRC) incidence is increasing in low‐ and middle‐income countries, where late‐stage presentation is common and survival rates remain poor. Early‐detection programs are critical to improving outcomes. Methods: A longitudinal early‐detection study was conducted in Osun State, Nigeria. A 6‐month community awareness campaign was implemented with posters, radio jingles, social media, and messaging disseminated via health and religious institutions. CRC knowledge was assessed before and after the intervention with the validated Bowel Cancer Awareness Measure questionnaire. Individuals with indicators of CRC were referred from peripheral facilities to an early‐diagnosis (ED) clinic at a tertiary center. Demographic data, presenting features, and diagnostic outcomes were prospectively recorded. The primary end point was detection of advanced adenomas and CRC. Results: Of 497 eligible participants, 322 (64.8%) completed pre‐ and postcampaign surveys. Awareness of CRC improved from 54 (16.8%) to 311 (96.9%) ( p < .001). Good knowledge of CRC risk factors and symptoms also increased significantly ( p < .001). A total of 329 individuals were navigated to the ED clinic; 168 (51.1%) were eligible for the protocol, and 116 (73.0%) completed colonoscopy. CRC was diagnosed in four patients (3.4%), with stage 0 ( n = 2), II ( n = 1), and III ( n = 1). Advanced adenomas were identified in 11% of patients (13 of 116) who underwent colonoscopy. Conclusions: Combining community engagement with patient navigation significantly increased CRC awareness and enabled the detection of advanced adenomas and early‐stage cancers. Expanding this model to a national level is recommended to evaluate broader impact, cost‐effectiveness, and potential implementation challenges.
- Open Access
Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma
Background: The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], ≥30) and biologic sex (male or female) for outcomes in patients with PDAC undergoing a surgery‐first approach was investigated. Methods: A prospectively maintained pancreatic cancer database at the Memorial Sloan Kettering Cancer Center was queried to identify all patients undergoing surgery with a pathologic diagnosis of PDAC. Clinicodemographic variables, outcomes, and tumor mutational analyses for all available patients were collected. Cumulative incidence of first recurrence involving the liver was estimated via a cumulative incidence function. Multivariable Cox regression was used to investigate the association between BMI and sex for overall survival. Results: From 2012 to 2022, 939 patients were identified who underwent surgery with a final pathologic diagnosis of PDAC. Median age was 70 years, 52% were male, and 24% were obese (BMI, ≥30). When dichotomized by sex and obesity status (BMI, <30 or ≥30), females with obesity had the lowest cumulative incidence of liver recurrence at 12 and 24 months postsurgery compared to all other groups (13% [95% CI, 7.2%–20%] and 15% [8.7%–23%], respectively). Females with obesity had the longest median overall survival at 37 months. Conclusions: After curative surgery for pancreatic cancer, females with obesity have a significantly lower rate of liver recurrence and the longest median overall survival. This does not appear to be related to surgical quality, receipt of adjuvant therapy, or tumor mutational profile. Investigation into host immune, metabolic, and hormonal parameters is paramount to understanding these differences.
Open AccessInfluence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma
Background: The influence of obesity and sex on outcomes in pancreatic adenocarcinoma (PDAC) remains unclear. The association between obesity (body mass index [BMI], ≥30) and biologic sex (male or female) for outcomes in patients with PDAC undergoing a surgery‐first approach was investigated. Methods: A prospectively maintained pancreatic cancer database at the Memorial Sloan Kettering Cancer Center was queried to identify all patients undergoing surgery with a pathologic diagnosis of PDAC. Clinicodemographic variables, outcomes, and tumor mutational analyses for all available patients were collected. Cumulative incidence of first recurrence involving the liver was estimated via a cumulative incidence function. Multivariable Cox regression was used to investigate the association between BMI and sex for overall survival. Results: From 2012 to 2022, 939 patients were identified who underwent surgery with a final pathologic diagnosis of PDAC. Median age was 70 years, 52% were male, and 24% were obese (BMI, ≥30). When dichotomized by sex and obesity status (BMI, <30 or ≥30), females with obesity had the lowest cumulative incidence of liver recurrence at 12 and 24 months postsurgery compared to all other groups (13% [95% CI, 7.2%–20%] and 15% [8.7%–23%], respectively). Females with obesity had the longest median overall survival at 37 months. Conclusions: After curative surgery for pancreatic cancer, females with obesity have a significantly lower rate of liver recurrence and the longest median overall survival. This does not appear to be related to surgical quality, receipt of adjuvant therapy, or tumor mutational profile. Investigation into host immune, metabolic, and hormonal parameters is paramount to understanding these differences.